DK3109325T3 - Fremgangsmåder til at forudsige antikræftreaktion - Google Patents

Fremgangsmåder til at forudsige antikræftreaktion Download PDF

Info

Publication number
DK3109325T3
DK3109325T3 DK16166825.6T DK16166825T DK3109325T3 DK 3109325 T3 DK3109325 T3 DK 3109325T3 DK 16166825 T DK16166825 T DK 16166825T DK 3109325 T3 DK3109325 T3 DK 3109325T3
Authority
DK
Denmark
Prior art keywords
cancer
dna
nucleic acid
chromosomal
tumor
Prior art date
Application number
DK16166825.6T
Other languages
English (en)
Inventor
Andrea L Richardson
Zhigang C Wang
Daniel P Silver
Zoltan Szallasi
Nicolai Juul Birkbak
Aron C Eklund
Original Assignee
Dana Farber Cancer Inst Inc
Brigham & Womens Hospital Inc
Childrens Medical Center
The Technical Univ Of Denmark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Brigham & Womens Hospital Inc, Childrens Medical Center, The Technical Univ Of Denmark filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of DK3109325T3 publication Critical patent/DK3109325T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Claims (10)

1. Fremgangsmåde til at bestemme en egnet behandlingsform for et individ med kræft, omfattende: i en biologisk prøve, som omfatter tumorceller fra et individ, at bestemme antallet af allel-ubalancer, der forekommer i en flerhed af kromosomale regioner, der strækker sig imod og omfatter mindst en telomer, men ikke krydser centromeren, hvor, når der er et større antal allel-ubalancer i forhold til en kontrol, en behandlingsform, der omfatter mindst et platin-baseret kemoterapeutisk middel eller mindst en poly(ADP-ribose)-polymerase (PARP)-inhibitor, bestemmes at være en egnet behandlingsform, og når der ikke er et større antal allel-ubalancer i forhold til en kontrol, en behandlingsform, der hverken omfatter et platinbaseret kemoterapeutisk middel eller en poly(ADP-ribose)-polymerase (PARP)-inhibitor, bestemmes at være en egnet behandlingsform.
2. Fremgangsmåde ifølge krav 1, hvor antallet af allel-ubalancer bestemmes ved at detektere en flerhed af heterozygotiske SNPs i flerheden af kromosomale regioner, der strækker sig imod og omfatter mindst en telomer, men ikke krydser centromeren.
3. Fremgangsmåde ifølge krav 1, hvor mindst en af de kromosomale regioner, der strækker sig imod og omfatter mindst en telomer, men ikke krydser centromeren, er mindst 5 Mb.
4. Fremgangsmåde ifølge krav 1, hvor mindst en af de kromosomale regioner, der strækker sig imod og omfatter mindst en telomer, men ikke krydser centromeren, er mindst 10 Mb.
5. Fremgangsmåde ifølge krav 1, hvor det mindst ene platin-holdige kemote-rapeutiske middel er udvalgt fra gruppen bestående af: cisplatin, carboplatin, oxaliplatin, nedaplatin og iproplatin.
6. Fremgangsmåde ifølge krav 1, hvor den mindst ene poly(ADP-ribose)-poly-merase (PARP)-inhibitor er udvalgt fra gruppen bestående af: Olaparib, ABT-888, BSI-201, INO-1001, PJ34, 3-aminobenzamid, 4-amino-1,8-naphthalimid, 6(5H)-phenanthridinon, benzamid, NU1025 og BGP-15.
7. Fremgangsmåde ifølge krav 1, hvor det at bestemme antallet af allel-ubalancer omfatter mindst en nukleinsyresekvenseringsteknik.
8. Fremgangsmåde ifølge krav 7, hvor den mindst ene nukleinsyresekvenseringsteknik omfatter next-generation-sekvensringssystemer.
9. Fremgangsmåde ifølge krav 1, hvor flerheden af allel-ubalancer omfatter mindst 5 allel-ubalancer.
10. fremgangsmåde ifølge krav 1, hvor kræften er udvalgt fra gruppen bestående af: brystkræft, æggestokkræft, overgangscelle-blærekræft, bronchogen lunge-kræft, skjoldbruskkirtel kræft, bugspytkirtelkræft, prostata kræft, livmoderkræft, testikelkræft, gastrisk kræft, blødvævs- og osteogene sarkomer, neu-roblastom, Wilms tumor, malignt lymfom (Hodgkins og ikke-Hodgkins), akut myeloblastær leukæmi, akut lymfoblastisk leukæmi, Kaposis sarkom, Ewings tumor, kolonkræft, melanom såsom refraktær myelomatose, og pladecellekar-cinomer i hovedet, nakken, halsen og vagina.
DK16166825.6T 2010-08-24 2011-08-19 Fremgangsmåder til at forudsige antikræftreaktion DK3109325T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40211610P 2010-08-24 2010-08-24
EP11757992.0A EP2609216B1 (en) 2010-08-24 2011-08-19 Methods for predicting anti-cancer response

Publications (1)

Publication Number Publication Date
DK3109325T3 true DK3109325T3 (da) 2019-01-28

Family

ID=44653534

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16166825.6T DK3109325T3 (da) 2010-08-24 2011-08-19 Fremgangsmåder til at forudsige antikræftreaktion
DK11757992.0T DK2609216T3 (da) 2010-08-24 2011-08-19 Fremgangsmåder til at forudsige antikræftreaktion

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11757992.0T DK2609216T3 (da) 2010-08-24 2011-08-19 Fremgangsmåder til at forudsige antikræftreaktion

Country Status (8)

Country Link
US (2) US9512485B2 (da)
EP (2) EP2609216B1 (da)
AU (1) AU2011293635B2 (da)
CA (1) CA2807823C (da)
DK (2) DK3109325T3 (da)
ES (2) ES2588979T3 (da)
NZ (1) NZ606725A (da)
WO (1) WO2012027224A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807823C (en) 2010-08-24 2023-02-07 The Brigham And Women's Hospital, Inc. Methods for predicting anti-cancer response
WO2012174378A2 (en) 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
AU2012358244A1 (en) 2011-12-21 2014-06-12 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
DK2817630T3 (da) * 2012-02-23 2018-10-08 Childrens Medical Center Fremgangsmåder til at forudsige en anti-cancer-reaktion
AU2013262655A1 (en) * 2012-05-16 2014-12-04 John Wayne Cancer Institute Immunological markers for adjuvant therapy in melanoma
CA3190075A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
WO2014113204A1 (en) 2013-01-17 2014-07-24 Personalis, Inc. Methods and systems for genetic analysis
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
WO2014165785A2 (en) * 2013-04-05 2014-10-09 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
EP3965111A1 (en) 2013-08-30 2022-03-09 Personalis, Inc. Methods and systems for genomic analysis
GB2535066A (en) 2013-10-03 2016-08-10 Personalis Inc Methods for analyzing genotypes
WO2015086473A1 (en) 2013-12-09 2015-06-18 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US20180163271A1 (en) * 2014-01-16 2018-06-14 Clovis Oncology, Inc. Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity
WO2015134548A1 (en) * 2014-03-05 2015-09-11 Sorrento Therapeutics, Inc. Methods for determining the maximum achievable response for a cancer treatment agent
DK3180447T3 (da) 2014-08-15 2020-06-15 Myriad Genetics Inc Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens
WO2016070131A1 (en) 2014-10-30 2016-05-06 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
EP3230472A4 (en) * 2014-12-08 2018-06-13 Myriad Genetics, Inc. Methods and materials for predicting response to niraparib
CA2996426A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
WO2017062434A1 (en) * 2015-10-07 2017-04-13 Mayo Foundation For Medical Education And Research Homologous recombination deficiency-interstitial aberration (hrd-ia) assay
WO2017165270A1 (en) * 2016-03-21 2017-09-28 Myriad Genetics, Inc. Homologous recombination deficiency to predict neoadjuvant chemotherapy necessity in bladder cancer
WO2017178509A1 (en) 2016-04-12 2017-10-19 Xentech Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
GB201609977D0 (en) * 2016-06-08 2016-07-20 Cancer Rec Tech Ltd Chemosensitivity predictive biomarkers
EP4302835A3 (en) 2016-06-29 2024-03-20 Tesaro, Inc. Methods of treating ovarian cancer
JP2020520921A (ja) 2017-05-18 2020-07-16 テサロ， インコーポレイテッド 癌を処置する併用療法
SG11202002862RA (en) 2017-09-30 2020-04-29 Tesaro Inc Combination therapies for treating cancer
MX2020003799A (es) 2017-10-06 2020-11-06 Tesaro Inc Terapias de combinacion y usos de las mismas.
CN111801117A (zh) 2017-12-27 2020-10-20 特沙诺有限公司 治疗癌症的方法
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
EP3945525A1 (en) 2020-07-27 2022-02-02 Sophia Genetics S.A. Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data
JP2024509887A (ja) * 2021-03-09 2024-03-05 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド Ｅｐ３００分解剤および神経芽細胞腫におけるその使用
WO2024083971A1 (en) 2022-10-19 2024-04-25 Vib Vzw Method of determining loss of heterozygosity status of a tumor

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
GB1432563A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum- co-ordination compounds
GB1432562A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum co-ordination compounds
ES444380A1 (es) 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4950738A (en) 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
DE3630497A1 (de) 1986-09-08 1988-03-10 Behringwerke Ag Cis-platin-komplexe, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel
DK252688A (da) 1987-05-08 1988-11-09 Sankyo Co Antitumorplatinkomplekser, fremgangsmaade til fremstilling deraf, samt deres terapeutiske anvendelse
US4996337A (en) 1987-06-23 1991-02-26 American Cyanamid Company Synthesis of cisplatin analogs
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US5434256A (en) 1988-11-22 1995-07-18 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US4946954A (en) 1989-01-17 1990-08-07 Georgetown University Platinum pharmaceutical agents
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
AU647741B2 (en) 1989-12-01 1994-03-31 Regents Of The University Of California, The Methods and compositions for chromosome-specific staining
US5295944A (en) 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
DK0612248T3 (da) 1991-11-15 2003-12-08 Smithkline Beecham Corp Præparat, der indeholder cisplatin og topotecan som antitumormiddel
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
GB9620209D0 (en) 1996-09-27 1996-11-13 Cemu Bioteknik Ab Method of sequencing DNA
GB9626815D0 (en) 1996-12-23 1997-02-12 Cemu Bioteknik Ab Method of sequencing DNA
US6384210B1 (en) 1997-03-20 2002-05-07 University Of Washington Solvent for biopolymer synthesis, solvent microdroplets and methods of use
US6214821B1 (en) 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
GB9806324D0 (en) 1998-03-24 1998-05-20 Pharmacia & Upjohn Spa Antitumour synergetic composition
GB9808145D0 (en) 1998-04-17 1998-06-17 Zeneca Ltd Assay
US20030049613A1 (en) 1998-08-17 2003-03-13 Manuel Perucho Methods for identifying somatic changes in genomic sequences useful for cancer diagnosis and prognosis
US6465177B1 (en) 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
CA2356697C (en) 1999-01-06 2010-06-22 Cornell Research Foundation, Inc. Accelerating identification of single nucleotide polymorphisms and alignment of clones in genomic sequencing
US6261775B1 (en) 1999-04-09 2001-07-17 The Regents Of The University Of California Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma
US6274320B1 (en) 1999-09-16 2001-08-14 Curagen Corporation Method of sequencing a nucleic acid
US7858331B2 (en) 2000-11-03 2010-12-28 Dana Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
WO2002044183A2 (en) 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
MXPA04008477A (es) 2002-03-01 2005-10-26 Ravgen Inc Metodos para deteccion de trastornos geneticos.
AU2003291281A1 (en) * 2002-11-01 2004-06-07 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
GB0226595D0 (en) 2002-11-15 2002-12-24 Univ Belfast Cancer therapy determination
US20070004621A1 (en) 2003-02-12 2007-01-04 Viji Shridhar Bex4 nucleic acids, polypeptides, and method of using
US20040170983A1 (en) 2003-02-27 2004-09-02 Danenberg Kathleen D. Methods of determining a chemotherapuetic regimin based on loss of heterozygosity at the thymidylate synthase locus
US20050112604A1 (en) 2003-03-14 2005-05-26 Akihide Fujimoto Loss of heterozygosity of the DNA markers in the 12q22-23 region
US7754684B2 (en) 2003-06-11 2010-07-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
US7485707B2 (en) 2003-07-02 2009-02-03 Solux Corporation Thermally stable crystalline epirubicin hydrochloride and method of making the same
KR101138471B1 (ko) 2003-07-25 2012-04-25 화이자 인코포레이티드 트리시클로 ｐａｒｐ 저해제
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
EP1664070B1 (en) 2003-08-13 2008-08-13 University Of South Florida Methods for inhibiting tumor cell proliferation involving platinum complexes
US20080108057A1 (en) 2004-06-22 2008-05-08 Griffith Jeffrey K Allelic imbalance in the diagnosis and prognosis of cancer
US20060141497A1 (en) 2004-10-22 2006-06-29 Finkelstein Sydney D Molecular analysis of cellular fluid and liquid cytology specimens for clinical diagnosis, characterization, and integration with microscopic pathology evaluation
US7563570B2 (en) 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
US20070070349A1 (en) 2005-09-23 2007-03-29 Helicos Biosciences Corporation Optical train and method for TIRF single molecule detection and analysis
CA2599445C (en) 2005-03-09 2022-05-03 Abbott Laboratories Diagnostics method for identifying candidate patients for the treatment with trastuzumab
ES2404311T3 (es) 2005-04-12 2013-05-27 454 Life Sciences Corporation Métodos para determinar variantes de secuencias usando secuenciación ultraprofunda
AU2006238877A1 (en) 2005-04-21 2006-11-02 Alza Corporation Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes
WO2006128195A2 (en) 2005-05-27 2006-11-30 Dana-Farber Cancer Institute Methods of diagnosing and treating cancer by detection of chromosomal abnormalities
CN101495459A (zh) 2005-06-30 2009-07-29 比奥纽默里克药物公司 单吡咯配体铂类似物
CN101589154A (zh) 2005-09-21 2009-11-25 佰尔瑞溶液有限公司 单链引物-启动子-选择子构建体的ivt的应用
WO2008112193A1 (en) 2007-03-12 2008-09-18 Dana-Farber Cancer Institute Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents
JP5707132B2 (ja) 2007-09-07 2015-04-22 フルイダイム コーポレイション コピー数変動の決定、方法およびシステム
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
CN101888777A (zh) 2007-12-07 2010-11-17 彼帕科学公司 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症
US20090246789A1 (en) 2008-03-25 2009-10-01 University Of South Carolina Gene Mutation Profiling of CSMD1
WO2009148528A2 (en) * 2008-05-30 2009-12-10 Millennium Pharmaceuticals, Inc. Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment
JP5570516B2 (ja) * 2008-10-31 2014-08-13 アッヴィ・インコーポレイテッド 遺伝子コピー数の変化のパターンに基づいた結腸直腸癌のゲノム分類
US8206910B2 (en) 2008-12-08 2012-06-26 The Cleveland Clinic Foundation Targets for use in diagnosis, prognosis and therapy of breast cancer
KR100925337B1 (ko) 2009-05-25 2009-11-09 주식회사 마크로젠 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측
WO2011048495A1 (en) * 2009-10-19 2011-04-28 Stichting Het Nederlands Kanker Instituut Predicting benefit of anti-cancer therapy via array comparative genomic hybridization
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
EP2539468A4 (en) 2010-02-24 2013-08-28 Myriad Genetics Inc DIAGNOSTIC PROCEDURE INCLUDING LOSS OF HETEROZYGOTY
DK3012329T3 (da) 2010-06-18 2017-11-20 Myriad Genetics Inc Fremgangsmåder og materialer til at vurdere tab af heterozygositet
WO2012019000A2 (en) 2010-08-04 2012-02-09 On-Q-ity Biomarkers for the identification monitoring and treatment of ovarian cancer
CA2807823C (en) 2010-08-24 2023-02-07 The Brigham And Women's Hospital, Inc. Methods for predicting anti-cancer response
KR20230141927A (ko) 2010-12-30 2023-10-10 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
WO2012174378A2 (en) 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
AU2012358244A1 (en) 2011-12-21 2014-06-12 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
DK2817630T3 (da) 2012-02-23 2018-10-08 Childrens Medical Center Fremgangsmåder til at forudsige en anti-cancer-reaktion
CA3190075A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
WO2014165785A2 (en) 2013-04-05 2014-10-09 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
WO2015086473A1 (en) 2013-12-09 2015-06-18 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US20180163271A1 (en) 2014-01-16 2018-06-14 Clovis Oncology, Inc. Use of PARP Inhibitors to Treat Breast or Ovarian Cancer Patients Showing a Loss of Heterozygosity

Also Published As

Publication number Publication date
EP3109325B1 (en) 2018-12-26
ES2588979T3 (es) 2016-11-08
AU2011293635A1 (en) 2013-02-28
AU2011293635B2 (en) 2015-11-26
CA2807823C (en) 2023-02-07
CA2807823A1 (en) 2012-03-01
ES2704303T3 (es) 2019-03-15
EP2609216A1 (en) 2013-07-03
US20130281312A1 (en) 2013-10-24
US9512485B2 (en) 2016-12-06
DK2609216T3 (da) 2016-09-12
EP3109325A1 (en) 2016-12-28
EP2609216B1 (en) 2016-06-01
US10577662B2 (en) 2020-03-03
WO2012027224A1 (en) 2012-03-01
US20170037478A1 (en) 2017-02-09
NZ606725A (en) 2014-06-27

Similar Documents

Publication Publication Date Title
US10577662B2 (en) Methods for predicting anti-cancer response
US20220186311A1 (en) Methods for predicting anti-cancer response
AU2006326385B2 (en) Use of ROMA for characterizing genomic rearrangements
US20090155805A1 (en) Copy number alterations that predict metastatic capability of human breast cancer
JP2017532959A (ja) Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム
JP2017508442A (ja) Ｍｄｍ２阻害剤に対する感受性と関連する遺伝子シグネチャー
US8709723B2 (en) Integrated analyses of breast and colorectal cancers
US20220025466A1 (en) Differential methylation
WO2014160080A1 (en) Cancer diagnosis, treatment selection and treatment
US20050142585A1 (en) Determination of phenotype of cancer and of precancerous tissue